Last reviewed · How we verify

Methylaminolaevulinate cream

Joint Authority for Päijät-Häme Social and Health Care · Phase 1 active Small molecule

Methylaminolaevulinate cream is a Small molecule drug developed by Joint Authority for Päijät-Häme Social and Health Care. It is currently in Phase 1 development. Also known as: 16% Methylaminolaevulinate (Metvix, Galderma) cream, MAL.

At a glance

Generic nameMethylaminolaevulinate cream
Also known as16% Methylaminolaevulinate (Metvix, Galderma) cream, MAL
SponsorJoint Authority for Päijät-Häme Social and Health Care
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylaminolaevulinate cream

What is Methylaminolaevulinate cream?

Methylaminolaevulinate cream is a Small molecule drug developed by Joint Authority for Päijät-Häme Social and Health Care.

Who makes Methylaminolaevulinate cream?

Methylaminolaevulinate cream is developed by Joint Authority for Päijät-Häme Social and Health Care (see full Joint Authority for Päijät-Häme Social and Health Care pipeline at /company/joint-authority-for-p-ij-t-h-me-social-and-health-care).

Is Methylaminolaevulinate cream also known as anything else?

Methylaminolaevulinate cream is also known as 16% Methylaminolaevulinate (Metvix, Galderma) cream, MAL.

What development phase is Methylaminolaevulinate cream in?

Methylaminolaevulinate cream is in Phase 1.

Related